Delving into the Latest Updates on Beaufour-Ipsen (Tianjin) Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Endocrinology and Metabolic Disease

Neoplasms

Synthetic peptide

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1
Nervous System Diseases	1
Neoplasms	1

Top 5 Drug Type	Count

Synthetic peptide	1
Small molecule drug	1

Top 5 Target	Count

GnRHR(Gonadotropin-releasing hormone receptor)	1

The purpose of this study is to further characterize the clinical efficacy and safety of Lanreotide Autogel as a monotherapy for tumor control in Chinese participants in routine clinical practice to supplement the bridging study and support the clinical trial application. The medical records were reviewed approximately 48 weeks after the start of treatment with Lanreotide Autogel.

Start Date10 Feb 2022

Sponsor / Collaborator

Ipsen Pharma Biotech SAS

[+2]

CTR20211024 / CompletedPhase 3

一项评估曲普瑞林6个月制剂治疗中国中枢性性早熟儿科参试者的疗效和安全性的开放标签、多中心、单臂、III期研究

[Translation] An open-label, multicenter, single-arm, phase III study evaluating the efficacy and safety of a 6-month formulation of triptorelin in the treatment of Chinese pediatric participants with central precocious puberty

本试验的主要目的是评估曲普瑞林6个月缓释（PR）制剂用于治疗中国CPP儿童时，i.v.GnRH激发后在第6个月（第169日）LH水平受抑降至青春期前水平（定义为LH峰值≤5 IU/L）方面的疗效。

[Translation]

The primary objective of this trial was to evaluate the efficacy of a 6-month extended-release (PR) formulation of triptorelin in suppressing LH levels to prepubertal levels (defined as peak LH ≤5 IU/L) at month 6 (day 169) after i.v. GnRH challenge in Chinese children with CPP.

Start Date10 Aug 2021

Sponsor / Collaborator

Debiopharm Research & Manufacturing SA

[+2]

CTR20210552 / CompletedPhase 3

一项在无法切除的局部晚期或转移性1级或2级胃肠胰神经内分泌肿瘤的中国参试者中评估接受Lanreotide Autogel® 120mg深部皮下注射，每28日1次的疗效和安全性的3期、单臂、开放标签、多中心研究

[Translation] A Phase 3, single-arm, open-label, multicenter study evaluating the efficacy and safety of Lanreotide Autogel® 120 mg deep subcutaneously injected every 28 days in Chinese participants with unresectable locally advanced or metastatic grade 1 or 2 gastrointestinal pancreatic neuroendocrine tumors

在无法切除的局部晚期或转移性GEP-NET的中国参试者中评估接受Lanreotide Autogel® 120 mg持续24周治疗的疗效。评价持续48周的疗效及安全性。

[Translation]

To evaluate the efficacy of Lanreotide Autogel® 120 mg for 24 weeks in Chinese participants with unresectable locally advanced or metastatic GEP-NET. To evaluate the efficacy and safety of Lanreotide Autogel® for 48 weeks.

Start Date24 May 2021

Sponsor / Collaborator

Ipsen Pharma Biotech SAS

[+2]

100 Clinical Results associated with Beaufour-Ipsen (Tianjin) Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Beaufour-Ipsen (Tianjin) Pharmaceutical Co., Ltd.

Login to view more data

2

Literatures (Medical) associated with Beaufour-Ipsen (Tianjin) Pharmaceutical Co., Ltd.

Tianjin Huagong

Determination of lovastatin in red koji by HPLC

Author: Du, Shan

The objective of this paper was to establish a method for determination of lovastatin in red koji.ZORBAX SB-C₁₈ (4.6 mm x 250 mm, 5 μm) column was used and the mobile phase was methanol-0.02% phosphoric acid (75:25).The detection wavelength was at 237 nm, the flow rate was 1.0 mL/min.Results showed that the linear range was obtained between 1.1936-3.5808 μg (γ = 1) and the average recovery was 100.78%, with relative standard deviation of 1.40%.It was concluded that this method was convenient, rapid and was suitable for determination of lovastatin in red koji.

Tianjin Huagong

Quantitative determination of content of paeoniflorin in WuLing Granules with high performance liquid chromatography method

Author: Du, Shan

The objective of this paper is to study and establish the reversed phased high performance liquid chromatog. method for determination of paeoniflorin in WuLing Granules; Phenomenex (4.6 mm × 250 mm, 5 μm) column was used as stationary phase; the mobile phase was composed of methanol and water (25:75); the flow rate was 1.0 mL/min^-1; the UV absorbance detection wavelength was set at 230 nm; the external standard method was used.The calibration curve was linear within the range of 0.0225-0.3375 μg (r = 0.9999); the average recovery of Paeoniflorin was 102.50%, with RSD 1.42% (n = 9); this method was convenient, rapid, sensitive, reproducible and accurate.It can be used in determination of Paeoniflorin in WuLing Granules.

100 Deals associated with Beaufour-Ipsen (Tianjin) Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Beaufour-Ipsen (Tianjin) Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 28 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Approved

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Montmorillonite	Diarrhea More	Approved
Triptorelin Pamoate ( GnRHR )	-	Phase 3
Tasquinimod ( NIF )	Metastatic castration-resistant prostate cancer More	Suspended
AbobotulinumtoxinA (Ipsen Biopharm Ltd) ( SNAP25 )	Glabellar frown lines More	Pending
Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate	Gastrointestinal Diseases More	Pending